California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
IRVINE, Calif., Oct. 26, 2016 -- CombiMatrix Corporation (NASDAQ:CBMX) announces that it will release financial results for the three and nine months ended September 30, 2016 after market close on Wednesday, November 2, 2016. CombiMatrix management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
| Live Call: | U.S.: | (866) 634-2258 | ||
| International: | (330) 863-3454 | |||
| Live Webcast: | http://edge.media-server.com/m/p/moipsncy | |||
| The webcast replay will be archived for 30 days | ||||
| Replay: | U.S.: | (855) 859-2056 | ||
| International: | (404) 537-3406 | |||
| Passcode: | 93599356 | |||
| The telephone replay will be available for seven days | ||||
About CombiMatrix Corporation
CombiMatrix Corporation provides best-in-class molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. Our testing focuses on advanced technologies, including single nucleotide polymorphism (“SNP”) chromosomal microarray analysis (“CMA”), next generation sequencing (“NGS”), fluorescent in situ hybridization (“FISH”) and high resolution karyotyping. Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.
| Company Contact: | Investor Contact: | |
| Mark McDonough | LHA | |
| President & CEO, CombiMatrix Corporation | Jody Cain | |
| (949) 753-0624 | (310) 691-7100 | |
| [email protected] |
